The early detection of the onset of transplant rejection is critical for the long-term survival of patients. The diagnostic gold standard for detecting transplant rejection involves a core biopsy, which is invasive, has limited predictive power and carries a morbidity risk. Here, we show that nanoparticles conjugated with a peptide substrate specific for the serine protease granzyme B, which is produced by recipient T cells during the onset of acute cellular rejection, can serve as a non-invasive biomarker of early rejection. When administered systemically in mouse models of skin graft rejection, these nanosensors preferentially accumulate in allograft tissue, where they are cleaved by granzyme B, releasing a fluorescent reporter that filters into the recipient’s urine. Urinalysis then discriminates the onset of rejection with high sensitivity and specificity before features of rejection are apparent in grafted tissues. Moreover, in mice treated with subtherapeutic levels of immunosuppressive drugs, the reporter signals in urine can be detected before graft failure. This method may enable routine monitoring of allograft status without the need for biopsies.
Bibliographical noteFunding Information:
This work was funded by an NIH Director’s New Innovator Award DP2HD091793 awarded to G.A.K. and National Institutes of Health U01 AI132904 awarded to A.B.A. Q.D.M. is supported by the NSF Graduate Research Fellowships Program (Grant No. DGE-1650044). D.V.M. is supported by National Institutes of Health F30 award number DK109665. B.A.H is supported by the National Institutes of Health GT BioMAT Training Grant under Award Number 5T32EB006343. G.A.K. holds a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.